Top in endocrinology: Mortality risk after fractures; study on biosimilar insulin

Poor physical performance measures in older men predicted their mortality risk after a bone fracture. It was the top story in endocrinology last week.

Another top story was about biosimilar insulin and how it compares to insulin glargine for lowering HbA1c in adults with type 2 diabetes.

Read these and more top stories in endocrinology below:

Physical performance measures predict postfracture mortality risk for older men

Older men with worse grip strength, gait speed and chair stand times within 5 years before a fracture have increased risk for death, according to study findings published in the Journal of Bone and Mineral Research. Read more.

Biosimilar noninferior to insulin glargine with lower cost in type 2 diabetes

Among adults with type 2 diabetes, biosimilar insulin was noninferior to insulin glargine for lowering HbA1c, had similar safety and cost less, although not significantly, according to data. Read more.

HbA1c self-testing deemed feasible for Black adults with type 2 diabetes

HbA1c self-testing was deemed feasible in a cohort of Black adults with type 2 diabetes, though HbA1c values are slightly lower with self-testing compared with use of a DCA laboratory device, according to study data. Read more.

Targeting increased physical activity may help reproductive-aged women lower diabetes risk

Reproductive-aged women who had previous gestational diabetes or prediabetes were less likely to meet physical activity goals, particularly muscle strengthening activity, than their peers at lower diabetes risk, according to study data. Read more.

Mylan Pharmaceuticals recalls insulin glargine injection pens for potential missing labels

Mylan Pharmaceuticals has issued a voluntary recall of one batch of its 100 units/mL insulin glargine injection pens due to the potential for missing labels, according to a press release from the FDA. Read more.